Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADAMTS-13 siRNA
- Development stage
- Preclinical
- Lead developer
- University of Utah
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
ADAMTS-13 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the ADAMTS-13 gene, which encodes a zinc-containing metalloprotease primarily known for cleaving von Willebrand factor. In preclinical oncology research, specifically glioblastoma, this siRNA is utilized to investigate the role of endogenous ADAMTS-13 in tumor development and vascular phenotype development. Knockdown of ADAMTS-13 using this siRNA has been shown to inhibit vasculogenic mimicry, cell proliferation, and migration in glioblastoma cell lines such as LN-229 and endothelial cells like HUVECs. Furthermore, the reduction of ADAMTS-13 levels is associated with a decrease in the expression of vascular endothelial growth factor (VEGF), suggesting that ADAMTS-13 may regulate tumor growth and angiogenic functions.
- Other names
- ADAMTS13 siRNAADAMTS-13 siRNAADAMTS 13 siRNAsiRNA targeting ADAMTS-13
02
Targets
A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) mRNA
Beyond the preview
Go deeper on ADAMTS-13 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADAMTS-13 siRNA.